0HNZ.LSE Fagron NV
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 1.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0HNZ.LSE undervalued?
Graham numberThe Graham number of Fagron NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fagron NV fundamental analysis
No fundamental analysis for Fagron NV yet.
Fagron NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex …
Full company profileFagron NV financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fagron NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 422M | 434M | 472M | 535M | 556M | - | - | - |
| Gross Profit | 184M | 189M | 208M | 240M | 247M | - | - | - |
| Operating Income | 17.9M | 74.6M | 73.5M | 84.4M | 88.7M | - | - | - |
| Net Income | -20.6M | 46.7M | 42.5M | 41.1M | 59.6M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 868M | 594M | 683M | 801M | 753M | - | - | - |
| Total Liabilities | 718M | 413M | 477M | 559M | 500M | - | - | - |
| Shareholders' Equity | 150M | 181M | 206M | 242M | 253M | - | - | - |
| Cash & Short-term Investments | 75.0M | 60.8M | 77.6M | 107M | 84.2M | - | - | - |
| Total Debt | 290M | 284M | 266M | 351M | 284M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 67.5M | 84.2M | 73.3M | 77.2M | 93.0M | 78.4M | 109M | - |
| Capital Expenditure | 14.8M | 10.0M | 15.7M | 22.2M | 18.4M | 20.7M | 18.5M | - |
| Ratios | ||||||||
| ROE | -13.7% | 25.7% | 20.6% | 17.0% | 23.5% | - | - | - |
| ROA | -2.4% | 7.9% | 6.2% | 5.1% | 7.9% | - | - | - |
| Net Profit Margin | -4.9% | 10.8% | 9.0% | 7.7% | 10.7% | - | - | - |
| Debt to Equity | 1.94x | 1.56x | 1.29x | 1.45x | 1.12x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fagron NV dividends
Fagron NV has not paid dividends in the last 9 fiscal years.
Last stock split: 1202:1117 on Jun 17, 2016.
Who owns Fagron NV
- Insiders 0.30%
- Institutions 72.34%
- Public & others 27.37%
- Free float 65.9M
Fagron NV company profile
- Company name
- Fagron NV
- Ticker
- 0HNZ.LSE
- ISIN
- BE0003874915
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 4,880
- Fiscal year end
- December
- Address
- Venecoweg 20A, Nazareth, Belgium, 9810
- Phone
- 32 800 128 80
- Website
- fagron.com
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Fagron NV management
5- Mr. Rafael PadillaCEO & Executive Director · born 1978
- Ms. Karin de JongCFO & Executive Director · born 1979
- Ms. Vera BakkerChief Operating Officer · born 1972
- Ignacio ArtolaGlobal Head of Investor Relations
- Kenneth BonnellGlobal Head of Quality